After completion or early withdraw from the treatment protocol, patients will be enrolled into this long-term follow-up study. If patients do not enter this study right after leaving the treatment protocol, they may have the option to enter this study at any time within 15 years after the last lentiviral-based gene-edited immune cell infusion.

Some patients may require joining other Pell's gene-edited immune cell therapy study during participating in this long-term follow-up study. For such case, the patient could be enrolled into the new treatment protocol. Meanwhile, the patient can be remaining in this long-term follow-up protocol as an inactive participant.

No study drug or other planned treatment will be administered. Subjects who previously received Pell's lentiviral-based gene-edited immune cell therapy will be evaluated the safety and efficacy.

• Proportion of patients with any events of the following items which are suspected related to previous gene-edited immune cell therapy.

1. New malignancies
2. New incidence or exacerbation of a pre-existing neurologic disorder
3. New incidence or exacerbation of a prior rheumatologic or other autoimmune disorder
4. New incidence of a hematologic disorder, including hypogammaglobulinemia
5. New incidence of infection (potentially product-related)
6. Other than the above adverse events, which are suspected related to gene-edited immune cell therapy judged by the investigator

Proportion of patients with detectable RCL in peripheral blood by VSV-G(Vesicular stomatitis virus G) qPCR